The cost of dabigatran varies significantly depending on factors such as dosage, prescription insurance coverage, and pharmacy. Without insurance, a 30-day supply of dabigatran can range from approximately $100 to over $400 [1]. For example, a 150 mg dose taken twice daily might cost around $200-$300 without insurance [1].
How much does dabigatran cost with insurance?
With prescription drug insurance, the out-of-pocket cost for dabigatran is typically lower. Co-pays can range from a few dollars to $50 or more per month, depending on the specific insurance plan and its formulary [1]. Some Medicare Part D plans, for instance, may have co-pays as low as $0 to $10 for a 30-day supply of dabigatran [1].
Can I get financial assistance for dabigatran?
Financial assistance programs may be available to help reduce the cost of dabigatran. The manufacturer of Pradaxa, dabigatran's brand name, offers a savings card that can reduce co-pays for eligible commercially insured patients to as little as $0 for a 30-day supply [2]. Patient assistance programs through various non-profit organizations may also provide support for individuals who meet certain income requirements [1].
When does dabigatran patent exclusivity expire?
Dabigatran's patent exclusivity has largely expired in major markets, allowing for the development and introduction of generic versions. For example, U.S. patent exclusivity for dabigatran expired in 2020, opening the door for generic competition [3]. The expiration of patents is a key factor in the potential reduction of drug costs as generic alternatives become available.
What are the generic options for dabigatran?
Following patent expirations, generic versions of dabigatran have become available. These generic formulations offer a more affordable alternative to the brand-name drug, Pradaxa.
How does dabigatran compare to other blood thinners?
Dabigatran is an oral anticoagulant that works by inhibiting thrombin, a key protein in the blood clotting process. It is often prescribed for conditions such as atrial fibrillation to prevent stroke and blood clots, and to treat deep vein thrombosis (DVT) and pulmonary embolism (PE) [4]. Compared to warfarin, dabigatran does not require regular blood monitoring and has fewer dietary restrictions [4]. Other direct oral anticoagulants (DOACs) like rivaroxaban, apixaban, and edoxaban also offer similar benefits and are frequently compared with dabigatran in terms of efficacy, safety profiles, and cost [4].